With patent expiries in the US dwindling from $30b in 2012 to $10b in 2013 (small molecules), Indian generic companies will now need to focus on complex generics that offer sustainability of earnings.
(PRWEB) February 26, 2013
India pharma rode on the wave of bunched up patent expiries in the US with many Para IV launches in 2012. In addition, it also benefited from the continuing high teen growth of Indian pharma market. With patent expiries in the US dwindling from $30b in 2012 to $10b in 2013 (small molecules), Indian generic companies will now need to focus on complex generics that offer sustainability of earnings. Locally acting drugs and targeted drug delivery products make up for the bulk of complex formulation generics. We have analyzed this space and have provided a fairly comprehensive list of products falling under these categories indicating that topical drugs remains the most near term opportunity for generics. Inhalers offer the most lucrative opportunity, though not before 2016.
Growth outlook on Indian market continues to remain optimistic with 15-18% growth. This is based on the silent reforms in India that started with implementation of a strict GMP (Good Manufacturing Practices) in 2005, continued with implementation of GLP (Good Laboratories Practices) in 2011 and now the bar coding norms at primary and secondary levels. All these continue to put pressure on the very small manufacturer ultimately leading to industry consolidation – something that augurs well for world’s most fragmented pharma market. We do not see any negative impact due to the newly announced National Pharma Pricing Policy (NPPP) due to its emphasis on market price based pricing policy.
Sun Pharma remains the best positioned to tide over the patent cliff with its latest acquisitions, DUSA and URL Pharma. A strong balance sheet further allows it to acquire more such high value targets. We also recommend Natco Pharma for its focus on complex generics like Copaxone, Revlimid and Tamiflu. Besides this, its domestic market strategy targeted at gaining Compulsory License on high value oncology products too remains lucrative.
Leading players featured include Natco, Ipca, Sun Pharma, Cadila Healthcare, Cipla, Lupin, Dr Reddy’s, Biocon, Ranbaxy, Aurobindo, and Dishman.
For more information please visit http://www.researchandmarkets.com/research/fxkpl4/global.
Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716